Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heterozygous deficiency of hypoxia-inducible factor–2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia
Koen Brusselmans, Veerle Compernolle, Marc Tjwa, Michael S. Wiesener, Patrick H. Maxwell, Désiré Collen, Peter Carmeliet
Koen Brusselmans, Veerle Compernolle, Marc Tjwa, Michael S. Wiesener, Patrick H. Maxwell, Désiré Collen, Peter Carmeliet
View: Text | PDF
Article Vascular biology

Heterozygous deficiency of hypoxia-inducible factor–2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia

  • Text
  • PDF
Abstract

Chronic hypoxia induces pulmonary vascular remodeling, leading to pulmonary hypertension, right ventricular hypertrophy, and heart failure. Heterozygous deficiency of hypoxia-inducible factor–1α (HIF-1α), which mediates the cellular response to hypoxia by increasing expression of genes involved in erythropoiesis and angiogenesis, has been previously shown to delay hypoxia-induced pulmonary hypertension. HIF-2α is a homologue of HIF-1α and is abundantly expressed in the lung, but its role in pulmonary hypertension remains unknown. Therefore, we analyzed the pulmonary response of WT and viable heterozygous HIF-2α–deficient (Hif2α+/–) mice after exposure to 10% O2 for 4 weeks. In contrast to WT mice, Hif2α+/– mice were fully protected against pulmonary hypertension and right ventricular hypertrophy, unveiling a critical role of HIF-2α in hypoxia-induced pulmonary vascular remodeling. Pulmonary expression levels of endothelin-1 and plasma catecholamine levels were increased threefold and 12-fold respectively in WT but not in Hif2α+/– mice after hypoxia, suggesting that HIF-2α–mediated upregulation of these vasoconstrictors contributes to the development of hypoxic pulmonary vascular remodeling.

Authors

Koen Brusselmans, Veerle Compernolle, Marc Tjwa, Michael S. Wiesener, Patrick H. Maxwell, Désiré Collen, Peter Carmeliet

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
(a) Western blot analysis showed that pulmonary HIF-2α protein levels we...
(a) Western blot analysis showed that pulmonary HIF-2α protein levels were decreased in Hif2α+/– mice compared with WT mice after normoxia (N) and after 1 week of hypoxia (H). Extracts from PC12 cells, exposed to normoxia or hypoxia (1% oxygen, 4 hours) as previously described (17, 26), were used as controls. (b) Systolic RV pressures in WT and Hif2α+/– mice under normoxia or after hypoxic exposure. Hemodynamic analysis revealed no differences in RV pressure under normoxia; however, WT mice showed increased RV pressure after 4 weeks of hypoxia, but Hif2α+/– mice did not. (c) RV hypertrophy analysis in WT and Hif2α+/– mice revealed no differences under normoxic conditions. After hypoxic exposure for 4 weeks, the ratio of the mass of the right ventricle to the mass of the left ventricle plus septum [RV/(LV+S)] was increased in WT mice but not in Hif2α+/– mice. (d) Pulmonary ET-1 transcript levels were increased in WT mice after exposure to chronic hypoxia for 6 days and were still elevated after 4 weeks of hypoxia. In contrast, chronic hypoxia failed to induce ET-1 expression in lungs of Hif2α+/– mice. Data represent means ± SEM of systolic RV pressure (mmHg; n = 4–7) (b), of the ratio of the mass of the right ventricle to the mass of the left ventricle plus septum [RV/(LV+S); n = 6–7] (c), and of the ET-1 mRNA copy number per 100 copies of HPRT (n = 5–6) (d). *Statistically significant (P < 0.05) vs. control (WT, normoxia).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts